GP

GSK plc

Sector-focusedQuality / disciplined sizing

Total reported value

$599.2M

Reporting period: 2026-03-31 · Number of holdings: 13

GSK plc disclosed 13 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $599.2M and a quarterly turnover rate of 36.9%.

Personality snowflake

Concentration
63.88
Portfolio Stability
36.93
Momentum/Contrarian
50
Sector conviction
100
Diversification
26
Sizing Uniformity
89.2

Recent moves

  • Trim WVE

    0.0%　-$177.9M

  • Add VIR

    0.0%　$25.1M

  • Add CRSP

    0.0%　-$15.7M

  • Add BNTX

    0.0%　-$5.6M

  • Add IDYA

    0.0%　-$1.7M

  • Add CYTK

    0.0%　$806.8K

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1CRSPCRISPR Therapeutics AGStock-Healthcare25.57%+4.43%—
2WVEWave Life Sciences Ltd.Stock-Other22.08%-16.74%—
3BNTXBiontech Se-adrStock-Other13.20%+2.60%—
4VIRVir Biotechnology INCStock-Other12.79%+6.34%—
5IDYAIdeaya Biosciences INCStock-Other7.41%+1.64%—
6LYELLyell Immunopharma INCStock-Other5.06%-0.77%—
7CYTKCytokinetics INCStock-Healthcare3.74%+1.03%—
8SPROSpero Therapeutics INCStock-Other3.59%+0.91%—
9FULCFulcrum Therapeutics INCStock-Other2.29%-0.24%—
10CVRXCvrx INCStock-Other1.59%+0.69%—
11BCYCBicycle Therapeutics Plc-adrStock-Other1.18%-0.18%—
12NKTXNkarta INCStock-Other1.11%+0.38%—
13RGNXRegenxbio INCStock-Other0.38%-0.11%—

Holding changes this quarter

GSK plc's most significant position changes for 2026-03-31: Sold out: Senseonics Holdings INC (SENS); Sold out: Harvard Bioscience INC (HBIOUSD).

Position changes disclosed by GSK plc for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1VIRVir Biotechnology INC+6.3%—Unchanged
2CRSPCRISPR Therapeutics AG+4.4%—Unchanged
3BNTXBiontech Se-adr+2.6%—Unchanged
4IDYAIdeaya Biosciences INC+1.6%—Unchanged
5CYTKCytokinetics INC+1%—Unchanged
6SPROSpero Therapeutics INC+0.9%—Unchanged
7CVRXCvrx INC+0.7%—Unchanged
8NKTXNkarta INC+0.4%—Unchanged
9RGNXRegenxbio INC-0.1%—Unchanged
10BCYCBicycle Therapeutics Plc-adr-0.2%—Unchanged
11FULCFulcrum Therapeutics INC-0.2%—Unchanged
12LYELLyell Immunopharma INC-0.8%—Unchanged
13WVEWave Life Sciences Ltd.-16.7%—Unchanged
14SENSSenseonics Holdings INC—EXITSold out
15HBIOUSDHarvard Bioscience INC—EXITSold out

FAQ

What is GSK plc and what type of investor is it?
GSK plc is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $599.2M, spread across 13 disclosed positions.
What are GSK plc's largest equity positions?
Based on the latest 13F filing, GSK plc's top holdings by market value are: 1. CRISPR Therapeutics AG (CRSP) — $153.2M (25.6%) 2. Wave Life Sciences Ltd. (WVE) — $132.3M (22.1%) 3. Biontech Se-adr (BNTX) — $79.1M (13.2%) 4. Vir Biotechnology INC (VIR) — $76.6M (12.8%) 5. Ideaya Biosciences INC (IDYA) — $44.4M (7.4%)
What changes did GSK plc make in its most recent portfolio filing?
In the latest quarter, GSK plc took a more defensive posture — trimming 0 positions and completely exiting 2 holdings. The largest of these moves: Sold out: Senseonics Holdings INC (SENS); Sold out: Harvard Bioscience INC (HBIOUSD)
What sectors does GSK plc focus on?
GSK plc is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 100.0%